Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease

被引：4
|
作者：
Newton, Chad A. [1 ]
Herzog, Erica L. [2 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Pulm & Crit Care Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
[2] Yale Univ, Yale Sch Med, Dept Med, Sect Pulm Crit Care & Sleep Med, 300 Cedar St TAC441S, New Haven, CT 06520 USA
来源：
CLINICS IN CHEST MEDICINE | 2021年 / 42卷 / 02期
关键词：
Interstitial lung disease; Biomarkers; Precision medicine; Omics; IDIOPATHIC PULMONARY-FIBROSIS; SURFACTANT PROTEIN-C; MUC5B PROMOTER POLYMORPHISM; GENE-EXPRESSION; TELOMERE LENGTH; MITOCHONDRIAL DYSFUNCTION; N-ACETYLCYSTEINE; DISTAL AIRWAYS; ASSOCIATION; SUSCEPTIBILITY;
D O I：
10.1016/j.ccm.2021.03.011
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
The clinical heterogeneity of ILD offers numerous opportunities for biomarker-based precision med-icine. Building up existing approaches, unbiased, omics-based methods could transform categori-zation and management of these disorders. Care-ful, practical, and collaborative approaches to biomarker discovery and validation may unveil new molecular endotypes and improve patient outcomes in this complex field.
引用
收藏
页码：357 / 364
页数：8
相关论文
共 50 条
  • [31] The promise and challenges of precision medicine in dilated cardiomyopathy
    Mason, Samantha
    Quinn, Ellie
    Halliday, Brian P.
    EUROPEAN HEART JOURNAL-CASE REPORTS, 2021, 5 (11)
  • [32] Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease
    Schniering, Janine
    Benesova, Martina
    Brunner, Matthias
    Feghali-Bostwick, Carol A.
    Schibli, Roger
    Distler, Oliver
    Mueller, Cristina
    Maurer, Britta
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [33] Therapeutic potential of traditional Chinese medicine for interstitial lung disease
    Zhou, Yan-Ming
    Dong, Xin-Ran
    Xu, Dong
    Tang, Jie
    Cui, Yuan-Lu
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 318
  • [34] Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease?
    Murray, Lynne A.
    Rubinowitz, Ami
    Herzog, Erica L.
    CURRENT OPINION IN RHEUMATOLOGY, 2012, 24 (06) : 656 - 662
  • [35] Tumour markers in rheumatoid arthritis-associated interstitial lung disease
    Wang, T.
    Zheng, X. -J.
    Ji, Y. -L.
    Liang, Z. -A.
    Liang, B. -M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 587 - 591
  • [36] Development of a scoring system with multidimensional markers for fibrosing interstitial lung disease
    Shenyun Shi
    Lulu Chen
    Xiaoqin Liu
    Min Yu
    Chao Wu
    Yonglong Xiao
    Scientific Reports, 12
  • [37] Development of a scoring system with multidimensional markers for fibrosing interstitial lung disease
    Shi, Shenyun
    Chen, Lulu
    Liu, Xiaoqin
    Yu, Min
    Wu, Chao
    Xiao, Yonglong
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [38] Radiomic texture-curvature (RTC) features for precision medicine of patients with rheumatoid arthritis-associated interstitial lung disease
    Watari, Chinatsu
    Matsuhiro, Mikio
    Nappi, Janne J.
    Nasirudin, Radin A.
    Hironaka, Toru
    Kawata, Yoshiki
    Niki, Noboru
    Yoshida, Hiroyuki
    MEDICAL IMAGING 2018: IMAGING INFORMATICS FOR HEALTHCARE, RESEARCH, AND APPLICATIONS, 2018, 10579
  • [39] Closing the Evidence Gap in Interstitial Lung Disease The Promise of Real-World Data
    Farrand, Erica
    Anstrom, Kevin J.
    Bernard, Gordon
    Butte, Atul J.
    Iribarren, Carlos
    Ley, Brett
    Martinez, Fernando J.
    Collard, Harold R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199 (09) : 1061 - 1065
  • [40] MOLECULAR TARGETED IMAGING BIOMARKERS FOR PERSONALIZED MEDICINE STRATEGIES IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE
    Schniering, J.
    Benesova, M.
    Brunner, M.
    Feghali-Bostwick, C.
    Schibli, R.
    Distler, O.
    Muller, C.
    Maurer, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 86 - 86
12345